Bioxcel Therapeutics, Inc., a Delaware corporation, was incorporated on March 29, 2017 and is a wholly-owned subsidiary of BioXcel. The company is a biopharmaceutical company that leverages artificial intelligence platforms to develop transformative drugs in neuroscience. Its commercial product IGALMI has been approved for the treatment of acute agitation associated with schizophrenia and bipolar disorder, and its R&D pipeline includes drug candidates for agitation of Alzheimer's disease and immuno-oncology assets.
